We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A non-beta-lactam antibiotic inhibitor for enterohemorrhagic Escherichia coli O104:H4.
- Authors
Wang, Haoqi; Jayaraman, Arul; Menon, Rani; Gejji, Varun; Karthikeyan, R.; Fernando, Sandun
- Abstract
The overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coli is regulated via production of β-lactam-hydrolyzing β-lactamases enzymes. Escherichia coli O104: H4 is a multi-drug resistant strain known to resist β-lactam as well as several other antibiotics. Here, we report a molecular dynamic simulation–combined docking approach to identify, screen, and verify active pharmacophores against enterohemorrhagic Escherichia coli (EHEC). Experimental studies revealed a boronic acid cyclic monomer (BACM), a non-β-lactam compound, to inhibit the growth of E. coli O104: H4. In vitro Kirby Bauer disk diffusion susceptibility testing coupled interaction analysis suggests BACM inhibits E. coli O104:H4 growth by not only inhibiting the β-lactamase pathway but also via direct inhibition of the penicillin-binding protein. These results suggest that BACM could be used as a lead compound to develop potent drugs targeting beta-lactam resistant Gram-negative bacterial strains. Key messages: • An in silico approach was reported to identify pharmacophores against E. coli O104: H4. • In vitro studies revealed a non-β-lactam compound to inhibit the growth of E. coli O104: H4. • This non-β-lactam compound could be used as a lead compound for targeting beta-lactam strains.
- Subjects
ESCHERICHIA coli O157:H7; BETA lactam antibiotics; DRUG resistance in bacteria; BORONIC acids; ESCHERICHIA coli; PENICILLIN-binding proteins
- Publication
Journal of Molecular Medicine, 2019, Vol 97, Issue 9, p1285
- ISSN
0946-2716
- Publication type
Article
- DOI
10.1007/s00109-019-01803-y